JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB290830

Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Trimeric Spike Glycoprotein

Be the first to review this product! Submit a review

|

(1 Publication)

Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Trimeric Spike Glycoprotein is a Full Length protein, in the 16 to 1190 aa range, expressed in HEK 293 cells, with 95%, suitable for SDS-PAGE.
1 Images
SDS-PAGE - Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Trimeric Spike Glycoprotein (AB290830)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Trimeric Spike Glycoprotein (AB290830)

SDS-PAGE analysis of ab290830 (3.5 μg).

Reducing conditions with Coomassie Blue staining.

Key facts

Purity

95% SDS-PAGE

Expression system

HEK 293 cells

Tags

His tag C-Terminus

Applications

SDS-PAGE

applications

Biologically active

No

Animal free

Yes

Carrier free

No

Storage buffer

pH: 7.4 Constituents: 99% DPBS

storage-buffer

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Recombinant SARS-CoV-2 Omicron variant Spike protein. Relative to Wuhan-Hu1 the protein has following amino acid changes: A67V, H69del, V70del, T95I, G142D, V143del, Y144del, Y145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F. The furin cleavage site has been altered to GSAS, and the protein has 6 amino acid changes in the S2 portion to stabilize trimer formation, commonly known as HexaPro. The C-terminus contains a T4 foldon domain.
style
left-column

Sequence info

[{"sequence":"VNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIIVEPERDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHGSASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSPIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFKGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGPALQIPFPMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTPSALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGGSGGSGGGSHHHHHHHHSAWSHPQFEKGGGSGGGSAWSHPQFEK","proteinLength":"Full Length","predictedMolecularWeight":"140 kDa","actualMolecularWeight":"180 kDa","aminoAcidEnd":1190,"aminoAcidStart":16,"nature":"Recombinant","expressionSystem":null,"accessionNumber":null,"tags":[{"tag":"His","terminus":"C-Terminus"}]}]
style
left-column

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Storage information
Avoid freeze / thaw cycle
False
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The SARS-CoV-2 Spike Glycoprotein also known as COVID-19 Spike Protein is a trimeric protein weighing approximately 180-200 kDa. It is located on the surface of the SARS-CoV-2 virus playing an important role in virus infectivity. The protein comprises two main subunits S1 and S2 which facilitate attachment to and fusion with host cells. The S1 subunit contains the receptor binding domain (RBD) which specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptor. The Spike Glycoprotein is expressed in infected host cells mainly in the respiratory tract allowing the virus to enter and initiate replication.
Biological function summary

The SARS-CoV-2 Spike Glycoprotein initiates viral entry by interacting with the host cell's ACE2 receptor which leads to viral fusion and entry into the cell's cytoplasm. The protein is part of the virion structure and forms the visible spike on the virion's surface. Upon binding a conformational change triggers the fusion of viral and cellular membranes a vital step for the viral lifecycle. The multimeric nature of the Spike Protein facilitates its interaction with antibodies including those known as 'anti-spike antibodies' which can neutralize the virus and prevent cell infection.

Pathways

The Spike Glycoprotein plays a significant role in the viral infection process and immune response pathways. It is central to the receptor-mediated endocytosis pathway where the virus is internalized into host cells. The protein’s interaction with ACE2 modifies downstream signaling pathways potentially altering host cell functions. Related proteins in these pathways include the ACE2 receptor and the cellular protease TMPRSS2 which primes the Spike Protein for fusion and viral entry.

The Spike Glycoprotein is chiefly implicated in COVID-19 the disease caused by SARS-CoV-2. The interaction with ACE2 is not just vital for infection but also contributes to the disease's symptomatology as ACE2 is involved in regulating blood pressure and inflammation. Additionally the Spike Protein's role in viral entry makes it a target for therapeutic interventions including 'anti-spike antibodies' and vaccines aimed at blocking this process to prevent infection. The protein's relevance to COVID-19 has led to significant interest in developing diagnostic and therapeutic tools such as 'antibodies COVID' that target the Spike Glycoprotein to manage the disease effectively.
style
left-column

Specifications

Form

Liquid

Additional notes

Purified from tissue culture supernatant.

style
left-column

General info

style
left-column

Product protocols

style
left-column

Target data

See full target information SARS-CoV-2 spike glycoprotein
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

International journal of molecular sciences 25: PubMed39201702

2024

Wuhan Sequence-Based Recombinant Antigens Expressed in Elicit Antibodies Capable of Binding with Omicron S-Protein.

Applications

Unspecified application

Species

Unspecified reactive species

Ekaterina Evtushenko,Ekaterina Ryabchevskaya,Angelina Kovalenko,Dmitriy Granovskiy,Marina Arkhipenko,Yuri Vasiliev,Nikolai Nikitin,Olga Karpova
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB283943

Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116] - BSA and Azide free

RabMAb|Recombinant

Flow Cytometry - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116] - BSA and Azide free (AB283943)

  • 0
  • 0
Proteins & Peptides

AB273530

Recombinant Human coronavirus SARS-CoV-2 nucleocapsid protein (His tag)

ELISA - Recombinant Human coronavirus SARS-CoV-2 nucleocapsid protein (His tag) (AB273530)

  • 0
  • 0
Secondary Antibodies

AB150113

Goat Anti-Mouse IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) (AB150113)

  • 5
  • 15
Primary Antibodies

AB9485

Anti-GAPDH antibody - Loading Control

BOND RX™ Validated|Lab Essentials

Immunocytochemistry/ Immunofluorescence - Anti-GAPDH antibody - Loading Control (AB9485)

  • 5
  • 88

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com